Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Five Prime Therapeutics Inc.

www.fiveprime.com

Latest From Five Prime Therapeutics Inc.

China Looms Large Seeking New Funding, Deals At J.P. Morgan

Chinese biotech companies are raising their profile and increasing their appeals to investors and partners at the J.P. Morgan Healthcare Conference. After billions in investment and increased activity in M&As, China is likely to remain attractive for international companies large and small vying for a slice of investment or pursuing innovative therapies.

China Emerging Markets

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.

Deals Business Strategies

Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

ImmunoOncology Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • FivePrime Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Five Prime Therapeutics Inc.
  • Senior Management
  • Lewis T Williams, MD, PhD, Pres. & CEO
    Marc Belsky, SVP, CFO
    Aron Knickerbocker, COO
    Francis Sarena, Chief Strategy Officer
    Helen Collins, MD, SVP, CMO
    Bryan Irving, PhD, SVP, Research
  • Contact Info
  • Five Prime Therapeutics Inc.
    Phone: (415) 365-5600
    111 Oyster Point Blvd.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register